---
title: "MiNK Therapeutics Stockholders Back Directors, Ratify Auditor"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290587375.md"
description: "MiNK Therapeutics held its Annual Meeting of Stockholders on June 17, 2026. Shareholders elected directors Garo Armen, Barbara Ryan, and John Holcomb to three-year terms and ratified KPMG LLP as the independent auditor. The company reported strong shareholder support for its leadership and governance framework."
datetime: "2026-06-23T15:15:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290587375.md)
  - [en](https://longbridge.com/en/news/290587375.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290587375.md)
generator: "portal-rs"
---

# MiNK Therapeutics Stockholders Back Directors, Ratify Auditor

### TipRanks' Prime Week Sale - 70% Off

-   Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
-   Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

MiNK Therapeutics ( (INKT) ) has shared an update.

MiNK Therapeutics held its Annual Meeting of Stockholders on June 17, 2026, with 3,277,906 shares, or 65.79% of eligible common stock, represented in person or by proxy, establishing a quorum for the session. Stockholders elected Class II directors Garo Armen, Barbara Ryan and John Holcomb to three-year terms expiring at the 2029 annual meeting, with each nominee receiving over 2.36 million votes and no votes cast against them.

At the same meeting, investors ratified the appointment of KPMG LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with 3,249,124 votes in favor and minimal opposition. The outcomes underscore solid shareholder support for MiNK’s current leadership and governance framework, reinforcing continuity in oversight and financial reporting as the company advances its operations in the competitive biotech arena.

The most recent analyst rating on (INKT) stock is a Buy  
 with a $35.00 price target.  
 To see the full list of analyst forecasts on MiNK Therapeutics stock,  
 see the INKT Stock Forecast page. 

**Spark’s Take on INKT Stock**

According to Spark, TipRanks’ AI Analyst, INKT is a Neutral.

Overall score is constrained primarily by weak financial performance (no revenue, persistent losses, negative cash flow, and negative equity/volatility). Technicals also lean bearish with the stock below key moving averages and negative MACD. These are partially offset by a relatively positive earnings-call outlook tied to randomized ARDS trial initiation, near-term data expectations, and manufacturing/partnership progress, while valuation inputs are limited given negative earnings and no dividend yield provided.

To see Spark’s full report on INKT stock,  
 click here. 

**More about MiNK Therapeutics**

MiNK Therapeutics operates in the biotechnology and pharmaceutical sector, focusing on the development of novel cell-based immunotherapies for cancer and other serious diseases, and targets patients and healthcare providers in specialized therapeutic markets.

**Average Trading Volume:** 48,767

**Technical Sentiment Signal:** Buy

**Current Market Cap:** $61.03M

Learn more about INKT stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [INKT.US](https://longbridge.com/en/quote/INKT.US.md)

## Related News & Research

- [MiNK Therapeutics (INKT) Q2 2026 Earnings Call: agenT-797 ARDS Trial Advances](https://longbridge.com/en/news/295902568.md)
- [Great Lakes Advisors LLC Acquires Shares of 66,924 Ionis Pharmaceuticals, Inc. $IONS](https://longbridge.com/en/news/296455358.md)
- [bioAffinity Technologies effects 1-for-15 reverse stock split effective Aug. 24, 2026](https://longbridge.com/en/news/296486716.md)
- [Insider Move at Arcutis Biotherapeutics Sends Strong Signal to Investors](https://longbridge.com/en/news/296853313.md)
- [Main Street Financial Solutions LLC Takes $1.66 Million Position in Amgen Inc. $AMGN](https://longbridge.com/en/news/296467702.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**